<- Go Home
Devyser Diagnostics AB (publ)
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.
Market Cap
SEK 2.3B
Volume
31.5K
Cash and Equivalents
SEK 100.4M
EBITDA
-SEK 29.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
SEK 191.8M
Profit Margin
81.58%
52 Week High
SEK 159.60
52 Week Low
SEK 83.30
Dividend
N/A
Price / Book Value
6.77
Price / Earnings
-49.91
Price / Tangible Book Value
7.12
Enterprise Value
SEK 2.2B
Enterprise Value / EBITDA
-175.28
Operating Income
-SEK 35.3M
Return on Equity
12.95%
Return on Assets
-4.64
Cash and Short Term Investments
SEK 100.4M
Debt
SEK 54.2M
Equity
SEK 338.0M
Revenue
SEK 235.1M
Unlevered FCF
-SEK 83.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium